Teva Pharmaceuticals Industries Limited announced it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business. Théramex brings to Teva a broad portfolio of women's health and gynecology products sold in over 50 countries, primarily France and Italy. Théramex's pipeline includes NOMAC/E2, a new oral contraceptive based on natural estrogens. Terms of the transaction were not disclosed.
Source
